PREVENT-AD Complete methods paper is available here

PUBMED ARTICLES

2023

Longitudinal blood biomarker trajectories in preclinical Alzheimer’s disease. Yakoub Y, Ashton NJ, Strikwerda-Brown C, Montoliu-Gaya L, Karikari TK, Kac PR, Gonzalez-Ortiz F, Gallego Rudolf J, Meyer PF, St-Onge F, Schöll M, Soucy JP, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S; PREVENT-AD Research Group. Alzheimers Dement. 2023 Jun 9.

https://doi.org/10.1002/alz.064811

Sex differences in associations between APOE ε2 and longitudinal cognitive decline. Wood ME, Xiong LY, Wong YY, Buckley RF, Swardfager W, Masellis M, Lim ASP, Nichols E, Joie R, Casaletto KB, Kumar RG, Dams-O’Connor K, Palta P, George KM, Satizabal CL, Barnes LL, Schneider JA, Pichet Binette A, Villeneuve S, Pa J, Brickman AM, Black SE, Rabin JS; ADNI and PREVENT-AD Research Groups. Alzheimers Dement. 2023 Mar 30.

doi: 10.1002/alz.13036

Sex-specific relationships between obesity, physical activity, and gray and white matter volume in cognitively unimpaired older adults. Intzandt B, Sanami S, Huck J, PREVENT-AD Research group, Villeneuve S, Bherer L, Gauthier CJ.  GeroScience. 2023 Jun;45(3):1869-1888. Epub 2023 Feb 13.

 doi: 10.1007/s11357-023-00734-4.

Resting-state MRI functional connectivity as a neural correlate of multidomain lifestyle adherence in older adults at risk for Alzheimer’s disease, Meishan Ai, Timothy P. Morris, Jiahe Zhang, Adrián Noriega de la Colina, Jennifer Tremblay-Mercier, Sylvia Villeneuve, Susan Whitfield-Gabrieli, Arthur F. Kramer & Maiya R. Geddes for the PREVENT-AD Research Group, Scientific Reports volume 13, Article number: 7487 (2023)

doi: 10.1038/s41598-023-32714-1

Aberrant neurophysiological signaling associated with speech impairments in Parkinson’s disease, Alex I Wiesman 1, Peter W Donhauser 1 2, Clotilde Degroot 1, Sabrina Diab 3, Shanna Kousaie 4, Edward A Fon 1, Denise Klein # 5 6, Sylvain Baillet # 7; PREVENT-AD Research Group; Quebec Parkinson Network, NPJ Parkinsons Dis 2023 Apr 14;9(1):61.

doi: 10.1038/s41531-023-00495-z.

A prognostic risk score for development and spread of chronic pain Christophe Tanguay-Sabourin, Matt Fillingim, Gianluca V. Guglietti, Azin Zare, Marc Parisien, Jax Norman, Hilary Sweatman, Ronrick Da-ano, Eveliina Heikkala, PREVENT-AD Research Group, Jordi Perez, Jaro Karppinen, Sylvia Villeneuve, Scott J. Thompson, Marc O. Martel, Mathieu Roy, Luda Diatchenko  & Etienne Vachon-Presseau, Nature medicine,  Published online: 06 July 2023,

https://doi.org/10.1038/s41591-023-02430-4

2022

Characterization of the contactin 5 protein and its risk-associated polymorphic variant throughout the Alzheimer’s disease spectrum. Tedeschi Dauar M., Labonté, A., Picard C., Miron J., Rosa-Neto P., Zetterberg H., Blennow K., Villeneuve S., Poirier, J. for the PREVENT-AD research group. Alzheimer’s Dement. 2022;1–15.

doi:10.1002/alz.12868

Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment, Cherie Strikwerda-Brown, Diana A. Hobbs, Julie Gonneaud, Frédéric St-Onge, Alexa Pichet Binette, Hazal Ozlen, Karine Provost, Jean-Paul Soucy, Rachel F. Buckley, Tammie L. S. Benzinger, John C. Morris, Victor L. Villemagne, Vincent Doré, Reisa A. Sperling, Keith A. Johnson, Christopher C. Rowe, Brian A. Gordon, Judes Poirier, John C. S. Breitner, Sylvia Villeneuve, for the PREVENT-AD, HABS, and AIBL Research Groups, JAMA Neurol. Published online July 30, 2022.

doi:10.1001/jamaneurol.2022.2379

Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition, Hazal Ozlen, Alexa Pichet Binette, Theresa Köbe, Pierre-François Meyer, Julie Gonneaud, Frédéric St-Onge, Karine Provost, Jean-Paul Soucy, Pedro Rosa-Neto, John Breitner, Judes Poirier, Sylvia Villeneuve, for the Alzheimer’s Disease Neuroimaging Initiative, the Harvard Aging Brain Study, the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease Research Group, JAMA Neurol. Published online August 22, 2022.

doi:10.1001/jamaneurol.2022.2442

Brain charts for the human lifespan, Bethlehem, R.A.I., J. Seidlitz, S. R. White, J. W. Vogel, K. M. Anderson, C. Adamson, S. Adler, G. S. Alexopoulos, E. Anagnostou, A. Areces-Gonzalez, D. E. Astle, B. Auyeung, M. Ayub, J. Bae, G. Ball, S. Baron-Cohen, R. Beare, S. A. Bedford, V. Benegal, F. Beyer, J. Blangero, M. Blesa Cábez, J. P. Boardman, M. Borzage, 3R-BRAIN, AIBL, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Repository Without Borders Investigators, CALM Team, Cam-CAN, CCNP, COBRE, cVEDA, ENIGMA Developmental Brain Age Working Group, Developing Human Connectome Project, FinnBrain, Harvard Aging Brain Study, IMAGEN, KNE96, The Mayo Clinic Study of Aging, NSPN, POND and The PREVENT-AD Research Group. Nature, Volume 604, 22 avril 2022.

https://doi.org/10.1038/s41586-022-04554-y

Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults. Meyer PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, Köbe T, Gonneaud J, Pichet Binette A, Ozlen H, Yakoub Y, Simrén J, Pannee J, Lantero-Rodriguez J, Labonté A, Baker SL, Schöll M, Vanmechelen E, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group., Ann Neurol. 2022 Apr;91(4):548-560. Epub 2022 Feb 18.

doi: 10.1002/ana.26308.

MSR1 and NEP Are Correlated with Alzheimer’s Disease Amyloid Pathology and Apolipoprotein Alterations. Miron J, Picard C, Labonté A, Auld D, Poirier J; PREVENT-AD research group. J Alzheimers Dis. 2022;86(1):283-296.

doi: 10.3233/JAD-215410.

2021

Association of a total cholesterol polygenic score with cholesterol levels and pathological biomarkers across the Alzheimer’s disease spectrum, Nathalie I. V. Nilsson, Cynthia Picard, Anne Labonté, Theresa Köbe, Pierre-François Meyer, Sylvia Villeneuve, Daniel Auld, Judes Poirier, for the PREVENT-AD research group and Alzheimer’s Disease Neuroimaging Initiative, Genes, 17 Nov 2021.

https://doi.org/10.3390/genes12111805

Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease, Julie Gonneaud, Alex Baria, Alexa Pichet Binette, Brian Gordon, Jasmeer Chhatwal, Carlos Cruchaga, Mathias Jucker, Johannes Levin, Stephen Salloway, Martin Farlow, Serge Gauthier, Tammie Benzinger, John Morris, Randall Bateman, John Breitner, Judes Poirier, Etienne Vachon-Presseau, Sylvia Villeneuve, ADNI Alzheimer’s Disease Neuroimaging Initiative, the Dominantly Inherited Alzheimer Network (DIAN), and the PREVENT-AD Research Group, Nature Communication (2021)

https://doi.org/10.1038/s41467-021-25492-9

Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer’s disease., Tremblay-Mercier J. Madjar C. Das S. Pichet Binette A. O.M.Dyke S. Étienne P. Lafaille-Magnan M-E, Remz J., Bellec P., Collins D.L., Rajah, M.N., Bohbot V., Leoutsakos J-M., Iturria-Medina Y., Kat J., Hoge R.D., Gauthier S., L.Tardif C. Chakravarty M.M., Poline J.B., Rosa-Neto P.,  C.Evans A., Villeneuve S., Poirier J., Breitner J., the PREVENT-AD Research Group, NeuroImage: Clinical, Volume 31, 2021, 102733, Accepted 14 June 2021, Available online 17 June 2021.

https://doi.org/10.1016/j.nicl.2021.102733

Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease. Binette AP, Theaud G., Rheault,F., Roy M., Collins DL, Mori H., Lee JH, Farlow MR,  Masters CL, Benzinger T., Morris, J., Bateman R., Breitner, JCS, Poirier J., Descoteaux M., Villeneuve S., DIAN Study Group and PREVENT-AD Research Group (2021). eLife 10:e62929.

https://doi.org/10.7554/eLife.62929

Sex differences in brain aging among adults with APOE4 genetic risk and family history of Alzheimer’s Disease. Subramaniapillai, S., Rajagopal, S., Snytte, J., Otto, A.R., the PREVENT-AD Research Group, Einstein, G., & Rajah, M.N. Neuroimage:Clinical. Accepted, February 24, 2021.

https://doi.org/10.1016/j.nicl.2021.102620

Generalization of memory-related brain function in asymptomatic older women with a family history of late onset Alzheimer’s Disease: Results from the PREVENT-AD Cohort. Rabipour S, Rajagopal S, Pasvanis S, Rajah MN. Neurobiology of Aging. 2021;104:42-56.

https://doi.org/10.1016/j.neurobiolaging.2021.03.009

The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Ossenkoppele R, Leuzy A, Cho H, Sudre CH, Strandberg O, Smith R, Palmqvist S, Mattsson-Carlgren N, Olsson T, Jögi J, Stormrud E, Ryu YH, Choi JY; The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD research group, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Borroni E, Klein G, Pontecorvo MJ, Devous MD Sr, Villeneuve S, Lyoo CH, Rabinovici GD, Hansson O. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2245-2258.

doi: 10.1007/s00259-020-05099-w.

Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer’s Disease. Pichet Binette A, Vachon-Presseau É, Morris J, Bateman R, Benzinger T, Collins DL, Poirier J, Breitner JCS, Villeneuve S; Dominantly Inherited Alzheimer Network (DIAN); PREVENT-AD Research Group. Biol Psychiatry. 2021 Apr 15;89(8):776-785. Epub 2020 Feb 6.

doi: 10.1016/j.biopsych.2020.01.023.

Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer’s disease: Vascular risk factors and functional connectivity changes. Köbe T, Binette AP, Vogel JW, Meyer PF, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Neuroimage. 2021 May 1;231:117832. Epub 2021 Feb 4.

doi: 10.1016/j.neuroimage.2021.117832. 

CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in healthy elderly with a parental history of Alzheimer’s disease. Poirier J., Nilsson N., Labonté, A., Auld D., Rosa Neto, P., Ashton N., Blennow K, Zetterberg, H, the Alzheimer’s Disease Neuroimaging Initiative, Breitner JCB, Villeneuve S., Picard C. for the PREVENT-AD research group. Alzheimer and Dementia, 17, e050342, 31 December 2021.

https://doi.org/10.1002/alz.050342

Characteristics of subjective cognitive decline associated with amyloid positivity. Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lleó A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Chételat G, Ruíz A, Marquié M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Binette AP, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, Sánchez-Saudinós MB, Ebenau J, Pocnet C, Eckerström M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ÅK, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L; Alzheimer’s Disease Neuroimaging Initiative; FACEHBI study group; PREVENT-AD research group, Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ. Alzheimers Dement. 2021 Dec 8.

doi: 10.1002/alz.12512.

2020

APOE4 status is related to differences in memory-related brain function in asymptomatic older adults with family history of Alzheimer’s disease: Baseline analysis of the PREVENT-AD task fMRI dataset. Rabipour, S., Rajagopal, S., Yu, E., Pasvanis, S., Lafaille-Magnan, M.E., Breitner, J., PREVENT-AD Group, and Rajah, M.N. (2020). Journal of Alzheimer’s Disease, 76 (1), 97-119.

doi: 10.3233/JAD-191292

Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease.  Gonneaud J., Bedetti C,  Pichet Binette A., Benzinger TLS, Morris J.C. Bateman R.J. Poirier J, Breitner JCS, Villeneuve S., DIAN Study Group and the PREVENT-AD Research Group, Neurology. 2020 Sep 15;95(11):e1554-e1564. Epub 2020 Aug 5.

doi: 10.1212/WNL.0000000000010314

Repetitive negative thinking is associated with amyloid, tau, and cognitive decline. Marchant L.N , Lovland L.R., Jones R, Pichet Binette A., Gonneaud J., Arenaza-Urquijo E. M., Chételat G., Villeneuve S., PREVENT-AD Research Group. Alzheimers Dement. 2020 Jul;16(7):1054-1064. Epub 2020 Jun 7.

doi: 10.1002/alz.12116

Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use. Köbe T, Gonneaud J, Pichet Binette A, Meyer PF, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group. JAMA Netw Open. 2020 Feb 5;3(2):e1920780.

doi: 10.1001/jamanetworkopen.2019.20780.

Intermediate flortaucipir uptake is associated with Aβ-PET and CSF-tau in asymptomatic adults. McSweeney M, Pichet Binette A, Meyer PF, Gonneaud J, Bedetti C, Ozlen H, Labonté A, Rosa-Neto P, Breitner J, Poirier J, Villeneuve S; PREVENT-AD Research Group. Neurology. 2020 Feb 3.

doi: 10.1212/WNL.0000000000008905. [Epub ahead of print]

Morphometric network differences in ageing versus Alzheimer’s disease dementia. Pichet Binette A, Gonneaud J, Vogel JW, La Joie R, Rosa-Neto P, Collins DL, Poirier J, Breitner JCS, Villeneuve S, Vachon-Presseau E; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group. Brain. 2020 Feb 1;143(2):635-649.

doi: 10.1093/brain/awz414.

2019

INTREPAD: a randomized trial of naproxen to slow progress of pre-symptomatic Alzheimer’s disease, Pierre François Meyer*, MSc; Jennifer Tremblay-Mercier*, MSc; Jeannie Leoutsakos, PhD; Cécile Madjar, MSc; Marie-Élyse Lafaille-Maignan, PhD; Melissa Savard, MSc; Pedro Rosa-Neto, MD, PhD; Judes Poirier, PhD**; Pierre Etienne, MD**; John Breitner, MD, MPH** for the PREVENT-AD research group. Neurology, 2019 Apr 5 [Epub ahead of print]

doi: 10.1212/WNL.0000000000007232.

No apparent effect of naproxen on CSF markers of innate immune activation, Meyer PF, Labonté A, Rosa-Neto P., Poirier, J. Breitner, J., & for the PREVENT-AD Research Group, BRIEF COMMUNICATION, Annals of Clinical and Translational Neurology, 06 June 2019.

https://doi.org/10.1002/acn3.788

Association of TLR4 with Alzheimer’s disease risk and presymptomatic biomarkers of inflammation, Justin Miron, Cynthia Picard, Marie-Élyse Lafaille-Magnan, Mélissa Savard, Anne Labonté, John Breitner, Pedro Rosa-Neto, Daniel Auld, Judes Poirier, for the PREVENT-AD research group, 4 June 2019, Alzheimer and dementia.

https://doi.org/10.1016/j.jalz.2019.03.012

Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression. Filip Liebsch, Luka Kulic, Charlotte Teunissen, Adeola Shobo, Irem Ulku, Vivienne Engelschalt, Mark A. Hancock, Wiesje M. van der Flier, Peter Kunach, Pedro Rosa-Neto, Philip Scheltens, Judes Poirier, Paul Saftig, Randall J. Bateman, John Breitner, Christoph Hock & Gerhard Multhaup. Nature Communications volume 10, Article number: 2240 (2019)

https://doi.org/10.1038/s41467-019-10152-w

MR-based age-related effects on the striatum, globus pallidus, and thalamus in healthy individuals across the adult lifespan. Tullo S, Patel R, Devenyi GA, Salaciak A, Bedford SA, Farzin S, Wlodarski N, Tardif CL; PREVENT-AD Research Group, Breitner JCS, Chakravarty MM. Hum Brain Mapp. 2019 Dec 15;40(18):5269-5288. Epub 2019 Aug 26.

doi: 10.1002/hbm.24771.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study. Picard C, Poirier A, Bélanger S, Labonté A, Auld D, Poirier J; PREVENT-AD Research Group. PLoS One. 2019 Aug 22;14(8):e0220254. eCollection 2019.
doi: 10.1371/journal.pone.0220254

https://doi.org/10.1371/journal.pone.0220254

Association of PPP2R1A with Alzheimer’s disease and specific cognitive domains. Miron J, Picard C, Labonté A, Auld D, Breitner J, Poirier J; United Kingdom Brain Expression Consortium; PREVENT-AD research group. Neurobiol Aging. 2019 Sep;81:234-243. Epub 2019 Jul 2.

doi: 10.1016/j.neurobiolaging.2019.06.008.

2018

Brain properties predict proximity to symptom onset in sporadic Alzheimer’s disease. Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P, Breitner JCS, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative and the PREVENT-AD Research Group. Brain. 2018 Apr 23.

doi: 10.1093/brain/awy093.

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis. Meyer PF, Savard M, Poirier J, Labonté A, Rosa-Neto P, Weitz TM, Town T, Breitner, J; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group. J Alzheimers Dis. 2018 Apr 11.

doi: 10.3233/JAD-170887.

A comparison of publicly available linear MRI stereotaxic registration techniques. Dadar M, Fonov VS, Collins DL; Alzheimer’s Disease Neuroimaging Initiative. Neuroimage. 2018 Jul 1;174:191-200. doi: 10.1016/j.neuroimage.2018.03.025. Epub 2018 Mar 13.

doi : 10.1016/j.neuroimage.2018.03.025

Subjective cognitive decline is associated with altered Default Mode Network connectivity in individuals with a family history of Alzheimer’s Disease, Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JC, Villeneuve S for the PREVENT-AD Research Group. Biological Psychiatry: Cognitive Neurosciences and Neuroimaging. May 2018

doi: 10.1016/j.bpsc.2017

Proximity to Parental Symptoms Onset and Amyloid-β Burden in sporadic Alzheimer disease. Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TL, Johnson SC, Breitner JC, Poirier J, for the Prevent-AD group. JAMA Neurology. 2018 May 1.

doi: 10.1001/jamaneurol.2017.5135.

2017

Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer’s disease, Tardif CL, Devenyi G, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner J, Chakravarty MM; PREVENT-AD Research Group., Hum Brain Mapp. 2017 Nov 21.

doi: 10.1002/hbm.23897

Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer’s Disease, Tuwaig, Miranda, Savard, Mélissa, Jutras, Benoît, Judes Poirier, Louis Collins, Pedro Rosa-Neto, David Fontaine and John C.S. Breitner for the PREVENT-AD Research Group, Journal of Alzheimer’s Disease, vol. 60, no. 4, pp. 1589-1600, 21 Aug 2017

doi: 10.3233/JAD-170545

Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer’s Disease. Dadar M, Pascoal TA, Manitsirikul S, Misquitta K, Fonov VS, Tartaglia MC, Breitner J, Rosa-Neto P, Carmichael OT, Decarli C, Collins DL. IEEE Trans Med Imaging. 2017 Aug;36(8):1758-1768.

doi: 10.1109/TMI.2017.2693978

Odor identification as a biomarker of preclinical AD in older adults at risk. Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS; PREVENT-AD Research Group. Neurology. 2017 Jul 25;89(4):327-335.

doi: 10.1212/WNL.0000000000004159

2016

Alzheimer’s Progression Score’: Development of a Biomarker Summary Outcome for AD Prevention Trials J.-M. Leoutsakos, A.L. Gross , R.N. Jones, M.S. Albert, J.C.S. Breitner (2016) The Journal of Prevention of Alzheimer’s Disease – JPAD© Volume 3, Number 4, 2016

doi: 10.14283/jpad.2016

Rationale and Structure for a new Center for Studies on Prevention of Alzheimer’s Disease (StoP-AD) J.C.S. Breitner, J. Poirier, P.E. Etienne1, J.M. Leoutsakos for the PREVENT-AD Research Group (2016) The Journal of Prevention of Alzheimer’s Disease – JPAD© Volume 3, Number 4, 2016

doi: 10.14283/jpad.2016.121.

2015

Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer’s disease. Orban P, Madjar C, Savard M, Dansereau C, Tam A, Das S, Evans AC, Rosa-Neto P, Breitner JC, Bellec P; PREVENT-AD Research Group. Sci Data. 2015 Oct 13;2:150043.

doi: 10.1038/sdata.2015.43.